net loss was $ 7.4 million or $ 0.19 per share versus net income of $ 13.4 million or $ 0.31 per diluted share .
as for our liquidity , we also have access to our $ 45 million credit facility , which today we have not drawn upon .
r&d expenses declined to $ 6.0 million from $ 6.6 million .
regarding biosimilar insulin aspart , the development of the product continues and we currently anticipate a potential launch of the product about 15 months following insulin glargine .
at june 30 , 2021 , cash and cash equivalents totaled approximately $ 93 million , up from $ 81 million at march 31 .
for fiscal 2022 , we expect net sales in the range of $ 400 million to $ 440 million , adjusted gross margin as a percentage of net sales of approximately 23 % to 25 % , adjusted r&d expense in the range of $ 26 million to $ 29 million , adjusted sg&a expense ranging from $ 58 million to $ 61 million , adjusted interest expense of approximately $ 52 million , the full year adjusted effective tax rate in the range of 21 % to 22 % , adjusted ebitda in the range of $ 40 million to $ 55 million , and lastly , capital expenditures to be approximately $ 12 million to $ 18 million .
the development arc for this product should be approximately 12 months to 18 months behind the generic flovent diskus product .
for example , our recent mycophenolate approval was achieved in just under 10 months , the third such product we developed to achieve so called first cycle approval in the past few years .
operating income was $ 4.9 million , compared with $ 26.7 million .
adjusted ebitda was $ 12.1 million .
we continue to launch products [ indecipherable ] approximately 13 andas pending at the fda including partner products , plus four additional products that are approved and pending launch .
we implemented and completed the cost reduction plan that included consolidating our r&d functions to a single location and lowered operating costs by approximately $ 15 million annually .
we also formed a new strategic alliance partnership to launch sevoflurane , a product with relatively few competitors and a market size of about $ 190 million based on iqvia data .
we also see opportunities to leverage our usa clinical data , 10 development and related ip , along with the manufacturing capacity at hec to form a strategic alliance with third parties looking to accelerate their access to insulin products in international markets such as europe .
